+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Myopia & Presbyopia Treatment Market - Global Forecast 2025-2032

  • PDF Icon

    Report

  • 198 Pages
  • October 2025
  • Region: Global
  • 360iResearch™
  • ID: 5012905
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior decision-makers face a complex and evolving landscape in the myopia and presbyopia treatment market as demographic shifts, technological advancements, and updated healthcare expectations are reshaping industry standards. Careful navigation and proactive strategy are essential to stay competitive and achieve sustainable growth.

Market Snapshot: Myopia & Presbyopia Treatment Market

The global myopia and presbyopia treatment market is gaining momentum due to rising demand for vision correction solutions. With a market valuation of USD 22.14 billion in 2024, this sector is projected to reach USD 24.13 billion in 2025, and is set for continued expansion at a 9.49% CAGR, targeting USD 45.77 billion by 2032. Several factors are driving this acceleration, including increasing prevalence of refractive issues, modernization across health systems, and greater adoption of advanced treatment options. Industry leaders face challenges such as shifting regulatory policies, evolving tariff structures, and the need to secure resilient supply chains.

Scope & Segmentation

This report delivers a comprehensive analysis of the myopia and presbyopia treatment market, segmented to support strategic decisions. The following areas highlight current trends, growth avenues, and stakeholder opportunities:

  • Treatment Type: Cataract surgery, a range of corrective lenses like contact lenses, orthokeratology and multifocal options, eyeglasses, implantable lenses, and surgical procedures specifically addressing refractive errors.
  • Age Group: Tailored approaches for adults, middle-aged individuals, older adults, and pediatric patients, accommodating unique disease trajectories and patient preferences.
  • Disease Type: Coverage of both myopia and presbyopia treatments, considering differences in clinical approaches and patient management pathways.
  • Distribution Channel: Integration of offline access through hospitals, specialty clinics, and optical stores, combined with a growing reliance on online models to enhance reach and patient engagement.
  • Geographical Coverage: In-depth analysis spans the Americas—encompassing the United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru—along with Europe, the Middle East & Africa, and Asia-Pacific, highlighting opportunities in mature and high-growth economies.
  • Company Profiles: Insight into leading organizations shaping the market, including ABB Optical Group, AbbVie Inc., AccuLens, Alcon Inc., ARCTIC VISION HONG KONG BIOTECH LIMITED, Bausch & Lomb Incorporated, Carl Zeiss AG, EssilorLuxottica, Euclid Systems Corporation, Eyenovia, Inc., Haag-Streit Group, HOYA Vision Care Europe Hoya Holdings N.V., Johnson & Johnson Vision Care, Inc., LENZ Therapeutics, Inc., Menicon Co., Ltd., NIDEK CO., LTD., Orasis Pharmaceuticals, Ltd, Regeneron Pharmaceuticals Inc., SCHWIND eye-tech-solutions GmbH, Sydnexis, Inc., The Cooper Companies Inc., Topcon Corporation, Ziemer Ophthalmic Systems AG.
  • Technology Focus: Emergent technologies include advanced multifocal lenses, minimally invasive surgical approaches, optical coherence tomography, wavefront aberrometry, digital screening solutions, and teleoptometry. These innovations are redefining diagnostic methods and treatment protocols across care pathways.

Key Takeaways for Strategic Decision-Makers

  • Teleoptometry and smartphone-based assessments are broadening access, particularly in regions with limited specialist availability or infrastructure.
  • Supply chain adaptability is increasingly necessary, enabling manufacturers to respond quickly to new regulatory mandates and sourcing uncertainties.
  • Personalized, patient-oriented solutions—supported by outcome tracking and direct engagement—are shaping research and development investments, driving improved patient satisfaction and adherence rates.
  • Strengthening the interface between optometry and primary care is improving consistency and efficiency in patient management.
  • Collaborative models involving manufacturers, payers, and technology partners are encouraging value-based care and supporting competitive positioning through unique service integration.
  • Regional differences in regulation, reimbursement, and technology adoption require a customized approach to market entry and expansion, supporting sustained local relevance and long-term competitiveness.

Tariff Impact: Navigating U.S. Tariff Volatility

The recent introduction of U.S. tariffs is adding cost uncertainties for manufacturers reliant on ophthalmic devices, raw materials, and specialty lens components. This dynamic is leading organizations to shift production closer to end-markets, embrace nearshoring, and diversify supplier bases to ensure continued access and mitigate risk exposure. These strategies are designed to protect financial sustainability while maintaining reliable patient care. At the same time, providers and payers are adapting pricing models to achieve a balance between sustainable market access and resilience against potential cost fluctuations.

Methodology & Data Sources

This market intelligence is constructed through interviews with industry leaders and medical experts, review of peer-reviewed literature, and secondary analysis of clinical registries, regulatory disclosures, and public domain data. Rigorous quantitative analytical techniques, such as regression and scenario modeling, validate trends and ensure reliability, while independent reviews reinforce accuracy.

Why This Report Matters

  • Empowers senior executives and strategic teams to act decisively in the face of shifting tariff, regulatory, and reimbursement frameworks within the vision correction ecosystem.
  • Identifies actionable innovation and growth opportunities by analyzing digital transformation, advanced technology integration, and diverse regional strategies for sustainable development.
  • Offers forward-looking insights that enable stakeholders to proactively manage risks, address disruption, and secure a strong competitive advantage within evolving global markets.

Conclusion & Future Outlook

The myopia and presbyopia treatment market is expected to evolve as new technologies, integrated care models, and agile supply strategies emerge. Aligning business direction with innovation, regulatory adaptation, and patient-centered approaches will be vital to long-term success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Rising adoption of low-dose atropine eye drops as first-line myopia control in children
5.2. Increased preference for extended depth of focus intraocular lenses for presbyopia correction in cataract surgeries
5.3. Growing investment in smart contact lens technologies for continuous myopia progression monitoring in adolescents
5.4. Surge in teleophthalmology platforms offering remote myopia management consultations and digital compliance tracking tools
5.5. Expansion of pharmaceutical research pipelines focusing on combined anti-myopia and presbyopia pharmacological therapies
5.6. Integration of 3D printed personalized spectacle lenses for bespoke myopia and presbyopia optical corrections
5.7. Emergence of blue light filtering lens coatings aiming to reduce digital eye strain associated with early presbyopia symptoms
5.8. Strategic partnerships between biotech startups and ophthalmic device manufacturers for innovative presbyopia treatment devices
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Myopia & Presbyopia Treatment Market, by Treatment Type
8.1. Cataract Surgery
8.2. Corrective Lenses
8.2.1. Contact Lenses
8.2.2. Eyeglasses
8.2.3. Multifocal Lenses
8.2.4. Orthokeratology Lenses
8.3. Implantable Lenses
8.4. Surgical Treatments
9. Myopia & Presbyopia Treatment Market, by Age Group
9.1. Adults
9.2. Middle-aged
9.3. Older Adults
9.4. Pediatric
10. Myopia & Presbyopia Treatment Market, by Disease Type
10.1. Myopia Treatment
10.2. Presbyopia Treatment
11. Myopia & Presbyopia Treatment Market, by Distribution Channel
11.1. Offline
11.1.1. Hospitals
11.1.2. Optical Stores
11.1.3. Specialty Clinics
11.2. Online
12. Myopia & Presbyopia Treatment Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Myopia & Presbyopia Treatment Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Myopia & Presbyopia Treatment Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. ABB Optical Group
15.3.2. AbbVie Inc.
15.3.3. AccuLens
15.3.4. Alcon Inc.
15.3.5. ARCTIC VISION HONG KONG BIOTECH LIMITED
15.3.6. Bausch & Lomb Incorporated.
15.3.7. Carl Zeiss AG
15.3.8. EssilorLuxottica
15.3.9. Euclid Systems Corporation
15.3.10. Eyenovia, Inc.
15.3.11. Haag-Streit Group
15.3.12. HOYA Vision Care Europe Hoya Holdings N.V.
15.3.13. Johnson & Johnson Vision Care, Inc.
15.3.14. LENZ Therapeutics, Inc.
15.3.15. Menicon Co., Ltd.
15.3.16. NIDEK CO., LTD.
15.3.17. Orasis Pharmaceuticals, Ltd
15.3.18. Regeneron Pharmaceuticals Inc.
15.3.19. SCHWIND eye-tech-solutions GmbH?
15.3.20. Sydnexis, Inc.
15.3.21. The Cooper Companies Inc.
15.3.22. Topcon Corporation
15.3.23. Ziemer Ophthalmic Systems AG
List of Tables
List of Figures

Samples

Loading
LOADING...

Companies Mentioned

The key companies profiled in this Myopia & Presbyopia Treatment market report include:
  • ABB Optical Group
  • AbbVie Inc.
  • AccuLens
  • Alcon Inc.
  • ARCTIC VISION HONG KONG BIOTECH LIMITED
  • Bausch & Lomb Incorporated.
  • Carl Zeiss AG
  • EssilorLuxottica
  • Euclid Systems Corporation
  • Eyenovia, Inc.
  • Haag-Streit Group
  • HOYA Vision Care Europe Hoya Holdings N.V.
  • Johnson & Johnson Vision Care, Inc.
  • LENZ Therapeutics, Inc.
  • Menicon Co., Ltd.
  • NIDEK CO., LTD.
  • Orasis Pharmaceuticals, Ltd
  • Regeneron Pharmaceuticals Inc.
  • SCHWIND eye-tech-solutions GmbH​
  • Sydnexis, Inc.
  • The Cooper Companies Inc.
  • Topcon Corporation
  • Ziemer Ophthalmic Systems AG

Table Information